Literature DB >> 20724984

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.

H Makishima, A M Jankowska, R V Tiu, H Szpurka, Y Sugimoto, Z Hu, Y Saunthararajah, K Guinta, M A Keddache, P Putnam, M A Sekeres, A R Moliterno, A F List, M A McDevitt, J P Maciejewski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20724984     DOI： 10.1038/leu.2010.167

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  72 in total

Review 1.  Pathogenesis and consequences of uniparental disomy in cancer.

Authors:  Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Clin Cancer Res       Date:  2011-04-25       Impact factor: 12.531

2.  A complex Polycomb issue: the two faces of EZH2 in cancer.

Authors:  Hanno Hock
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

3.  Epigenetics and mutations in chronic myeloproliferative neoplasms.

Authors:  Alessandro M Vannucchi; Flavia Biamonte
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

4.  GATA-1 utilizes Ikaros and polycomb repressive complex 2 to suppress Hes1 and to promote erythropoiesis.

Authors:  Julie Ross; Lionel Mavoungou; Emery H Bresnick; Eric Milot
Journal:  Mol Cell Biol       Date:  2012-07-09       Impact factor: 4.272

Review 5.  Mature T-cell leukemias: Molecular and Clinical Aspects.

Authors:  Nathanael G Bailey; Kojo S J Elenitoba-Johnson
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 6.  Emerging patterns of somatic mutations in cancer.

Authors:  Ian R Watson; Koichi Takahashi; P Andrew Futreal; Lynda Chin
Journal:  Nat Rev Genet       Date:  2013-09-11       Impact factor: 53.242

Review 7.  Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.

Authors:  Hideki Muramatsu; Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

Review 8.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

9.  High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.

Authors:  K C Kawabata; Y Hayashi; D Inoue; H Meguro; H Sakurai; T Fukuyama; Y Tanaka; S Asada; T Fukushima; R Nagase; R Takeda; Y Harada; J Kitaura; S Goyama; H Harada; H Aburatani; T Kitamura
Journal:  Leukemia       Date:  2017-07-19       Impact factor: 11.528

Review 10.  Deregulated Polycomb functions in myeloproliferative neoplasms.

Authors:  Goro Sashida; Motohiko Oshima; Atsushi Iwama
Journal:  Int J Hematol       Date:  2019-01-31       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.